TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05906511
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo and/or vaporized saline
Study: NCT05577455
Drug: Medical prescription before ovulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical prescription before ovulation, modified two solstices pill and Si-Wu-Tang: 15g of Nv Zhen Zi (Fructus Ligustri Lucidi), 10g of Mo Han Lian (Yerbadetajo herb), 15g of Gou Qi Zi (Fructus lycii), 20g of Tu Si Zi (Semen cuscutae), 15g of Shu Di (Radix Rehmanniae Preparata), 10g of Dang Gui (Angelica sinensis), 10g of Bai Shao (Paeonia lactiflora Pallas), 20g of Sheng Shan Yao (Rhizoma Dioscoreae), 15g of Fu Pen Zi (Raspberry), and 15g of Shan Yu Rou (Fructus corni). The medical prescription is initiated on the fifth day of menstruation and is taken continuously for 10-15 days.
Study: NCT06544473
Drug: 17-beta estradiol
Normalized name: 17-beta estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with orally administered estrogen for 14 days
Study: NCT06544473
Drug: 17-beta estradiol
Normalized name: 17-beta estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with transdermally administered estrogen for 14 days
Study: NCT05577455
Drug: Medical prescription after ovulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical prescription after ovulation, modified Er Xian decoction for promoting fertilization and Si-Wu-Tang: 10g of Xian Mao (Curculigo orchioides), 15g of Xian Ling Pi (Epimedium Herb), 15g of Ba Ji Tian (Morinda officinalis), 20g of Tu Si Zi (Semen cuscutae), 15g of Nv Zhen Zi (Fructus Ligustri Lucidi), 15g of Zi Shi Ying (Fluoritum), 15g of Shu Di (Radix Rehmanniae Preparata), 10g of Dang Gui (Angelica sinensis), 10g of Bai Shao (Paeonia lactiflora Pallas), and 10g of Chuan Xiong (Szechwan Lovage Rhizome). The medical prescription is administered continuously for 10-15 days after ovulation, based on follicle development and endometrial growth monitored by ultrasound.
Study: NCT05128825
Drug: ZN-c3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZN-c3 is an investigational drug.
Study: NCT05712200
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage Formulation: Liquid (in vial)~Dose Strength: Placebo to Abelacimab
Study: NCT06584799
Drug: Micronized purified flavonoid fraction
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized purified flavonoid fraction (MPFF) 1000. Active substance: micronized purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin). MPFF is a venotonic agent that also has angioprotective properties. It reduces venous distensibility and blood stasis, capillary permeability, and increases capillary resistance.~MOFF 1000 dosing regimen is 1000 mg once daily for 2 months.
Study: NCT04974008
Drug: OST31-164
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who will receive OST31-164 as a single agent every 3 weeks for 48 weeks with 4 doses constituting 1 treatment cycle (12 weeks per cycle). Each patient will receive treatment at a dose of 1x109 CFU until week 48 or until disease progression, unacceptable toxicity, or the patient meets any other treatment discontinuation criteria.
Study: NCT05419401
Drug: [14C]AZD5363 (Capivasertib)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for Infusion 20 µg/mL (NMT 37.0 kBq/5 mL) - 100 µg; 5 mL, Intravenous~Oral Solution, 400 mg (NMT 4.8 MBq) - 400mg; 100mL, oral, fasted
Study: NCT05607108
Drug: ZEN003694
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZEN003694 60mg po qd on a 5 days on 2 days off schedule in an every 21-day cycle
Study: NCT05593055
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After the Pre-Treatment Assessment, participants in the eplerenone arm will be given 50 mg eplerenone. At 2 weeks, eplerenone will be increased to 100 mg.
Study: NCT05593055
Drug: Chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the Pre-Treatment Assessment, participants in the chlorthalidone arm will be given 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium.
Study: NCT05974046
Drug: [14C]IDV184001AN
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]-IDV184001AN 200 mg/\~100 µCi/ 15 g oral suspension
Study: NCT06024239
Drug: Placebo for ABBV-932
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule; oral
Study: NCT04597372
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be prepared by the IDS pharmacist (or contracted pharmacy) and encapsulated in identical appearing wraps. Subjects will be provided with 10 capsules to be taken daily.
Study: NCT05537766
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT05949125
Drug: R-TM123
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion over 20 days
Study: NCT04815187
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will be given a drug diary to record when they took the drug and any symptoms that they are experiencing, and will bring this diary and any unused pills to their next clinic visit before receiving the next 30-day supply. This process will continue for the full 90 days of study involvement, with a final visit 3 months later.
Study: NCT05583344
Drug: GSK4532990
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK4532990 will be administered.
Study: NCT05583344
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered.
Study: NCT04677569
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral tablet
Study: NCT05652894
Drug: Investigator's Choice Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: bevacizumab 5mg/kg given by IV every 14 days. Other Name: Avastin~Drug: cetuximab 400 mg/sqm initial dose, then 250 mg/sqm once weekly thereafter. Other Name: Erbitux~Drug: oxaliplatin 8 5 mg/sqm by IV, day1. Component of mFOLFOX6.~Drug: irinotecan 180 mg/sqm by IV, day1.Component of FOLFORI.~Drug: calcium Folinate 400 mg/sqm by IV, day1.Component of mFOLFOX6 or FOLFORI.~Drug: 5-fluorouracil 400 mg/sqm, day1,followed by 2400 mg/sqm iv infusion over 46\~48 h.Component of mFOLFOX6 or FOLFORI.
Study: NCT06081530
Drug: Placebo matching BI 3802876
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 3802876
Study: NCT06499701
Drug: Ringer's Lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's Lactate is administered at a dose of 30ml/kg, with the first 20ml/kg given at a constant rate over the initial 30 minutes, followed by a 30-minute pause, and then an additional 10ml/kg over the next 15 minutes, completing the infusion within 75 minutes.
Study: NCT04934891
Drug: ION547
Approvals — FDA: no, EMA: no, PMDA: no
Description: ION547 will be administered by SC injection.
Study: NCT04934891
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ION547-matching placebo will be administered by SC injection.
Study: NCT04976387
Drug: Hydrocodone/Acetaminophen 5 Mg-325 Mg ORAL TABLET
Normalized name: hydrocodone/acetaminophen 5 mg-325 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are instructed to take Hydrocodone/acetaminophen 5 mg-325 mg oral tablets every 6 hours as needed for treatment of severe pain
Study: NCT04976387
Drug: Ibuprofen 600 mg
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will take ibuprofen 600 mg every 6 hours as needed
Study: NCT04976387
Drug: Acetaminophen 650 MG
Normalized name: acetaminophen 650 MG
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take Tylenol 650mg every 6 hours as needed
Study: NCT05318066
Drug: Ringer Lactate and Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm Fluids (FL)- 500 mL of ringer lactate over 10 minute prior to the administration of procedural medications.~Arm Vasopressor (VP)- Patients in this group would receive norepinephrine infusion at a dose of 0.08 μg/kg/min over 10 minutes prior and 5 minutes after tracheal intubation.
Study: NCT06580782
Drug: Standard Dose Synthetic Pitocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participant will receive thestandard-dose synthetic oxytocin for labor induction or augmentation.
Study: NCT06042257
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsule
Study: NCT06392841
Drug: Androgen Deprivation Therapy (ADT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical castration per ADT with GnRH agonist or antagonist (or surgical castration per orchiectomy)
Study: NCT05537987
Drug: ICP-723
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3+3 dose escalation
Study: NCT04523922
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intranasal saline spray) self administered 30 minutes prior to each COPE session.
Study: NCT06171932
Drug: Methylprednisolone,
Normalized name: methylprednisolone, micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention required
Study: NCT05989542
Drug: PLB1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg BID Oral
Study: NCT06156280
Drug: TQH2929 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQH2929 injection is a humanized monoclonal antibody that interfering with the signal cascade.
Study: NCT06156280
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT05611710
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo, with visually matched clear syringes~* Adults (≥16 years) and children (12-16 years, \> 50Kg) will receive 2 syringes of placebo via IV route, twice daily for 4 days~* Children (12-16 years, \< 50Kg) will receive no more than 1 syringe of placebo via IV route, twice daily for 4 days
Study: NCT05954338
Drug: DWC202307
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWC202307
Study: NCT05954338
Drug: DWJ1543
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWJ1543
Study: NCT05954338
Drug: DWC202216
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWC202216
Study: NCT04700709
Drug: Mycophenolate Mofetil Cap./Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 1g BID(total 2g daily), PO
Study: NCT01931501
Drug: Singulair® (Montelukast Sodium) Chewable Tablets 5mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05785754
Drug: DCSZ11
Approvals — FDA: no, EMA: no, PMDA: no
Description: A monoclonal antibody that binds to CD93, DCSZ11 will be administered as a single intravenous (IV) infusion on Day 1 in each 21-day cycle.
Study: NCT06267118
Drug: Hypertonic Saline Solution, 1 Ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilute 0.3 ml hypertonic saline with 3 ml normal saline for nebulization
Study: NCT05518838
Drug: OKN-007
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKN-007 is an intravenously administrated drug being developed as a novel anti-cancer therapy against gliomas.
Study: NCT05737771
Drug: DWC202213
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWC202213
Study: NCT05737771
Drug: DWJ1563
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWJ1563
Study: NCT05737771
Drug: DWP16001
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP16001
Study: NCT04837677
Drug: PRT1419
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRT1419 will be administered by intravenous infusion
Study: NCT05185011
Drug: TPN171H
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg TPN171H tablets，single dose
Study: NCT06037252
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06239298
Drug: ZG005 Powder for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion(IV), once every 3 weeks
Study: NCT05205928
Drug: Outpatient therapy: 11 weeks of drug therapy with usual treatment + 4 weeks of closed-loop therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The blinded drug will be used with participant's routine therapy (+ continuous glucose monitoring if not already in use) for 11 weeks with follow-up from qualified research personnel concerning pump settings, side effects, and incremental dose increase. While continuing to use the medication, there are 4 weeks of closed-loop pump therapy and drug use; glycemic outcomes will be taken from the last 4 weeks. This will be followed by laboratory and anthropometric testing, followed by 2 weeks of wash-out.
Study: NCT06066359
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by (IV) vein
Study: NCT06066359
Drug: NY-ESO-1 TCR/IL-15 NK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by (IV) vein
Study: NCT02431715
Drug: [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will have their weight and baseline vital signs recorded.~The study subject will have an intravenous catheter inserted and receive a slow bolus intravenous dose of 185 - 370 MBq (5 -10mCi) 18F-FDOPA.~The patient will rest in a comfortable reclining chair in a warm, private shielded room for 45 to 60 minutes.~Patients are positioned supine and centered on the scanner bed for an average total scan time (CT and PET) of approximately 30 minutes.~Images will be interpreted by qualified and experienced physicians. Findings of significance from the PET/CT scan, and any incidental findings of significance from the CT scan, will be included in the single final report that will be issued to referring physicians.
Study: NCT05834595
Drug: CKD-828, D064, D701
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT05495425
Drug: NPC-12Y gel
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPC-12Y gel is applied twice a day for 12 weeks. After the double-blind evaluation period, NPC-12Y gel is applied twice a day for 52 weeks.
Study: NCT05104476
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion
Study: NCT05495425
Drug: NPC-12Y placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPC-12Y placebo gel is applied twice a day for 12 weeks. After the double-blind evaluation period, NPC-12Y gel is applied twice a day for 52 weeks.
Study: NCT04923906
Drug: Aumolertinib
Normalized name: aumolertinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aumolertinib 110 mg QD in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of every 21-day cycles up to 4\~6 cycles, followed by Aumolertinib 100mg QD with pemetrexed maintenance (500 mg/m2) on Day 1 of every 21-day cycles.~Dose may be reduced to allow for the management of investigational drug related toxicity.
Study: NCT04923906
Drug: Placebo Aumolertinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Aumolertinib 110 mg QD Dose may be reduced to allow for the management of investigational drug related toxicity.
Study: NCT05655806
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: given as placebo
Study: NCT05656092
Drug: HIP0612
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug
Study: NCT06220838
Drug: SC-101
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive a single intravenous (IV) infusion of SC-101 once weekly.
Study: NCT05776056
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An inactive pill (placebo) will be taken twice daily.
Study: NCT04936035
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered by SC injection
Study: NCT05656092
Drug: HPP2202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug
Study: NCT05656092
Drug: RLD2204
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug
Study: NCT05656092
Drug: HPP2201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug
Study: NCT05102591
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention in syringe for target dose of 0.5 mg/kg, maximum 30 mg of ketorolac (1 mL), and administer as a direct IV push over 1-5 minutes
Study: NCT05102591
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl will be administered to participants through IV in identical dosages, methods, and duration as the ketorolac and metoclopramide interventions described above.
Study: NCT06149494
Drug: Vapendavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to the experimental cohort will be administered Vapendavir.
Study: NCT06149494
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to the placebo cohort will be administered placebo.
Study: NCT05524883
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by IV infusion
Study: NCT04949256
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m\^2 Q2W as part of investigator's choice mFOLFOX6 chemotherapy.
Study: NCT06327646
Drug: Multiple Micronutrient Supplement Blister
Normalized name: Blister Armour
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMS in a blister pack along with related job aids, counselling during ANC, etc.
Study: NCT06352541
Drug: PRO-232
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 0.5% and Dexamethasone Phosphate 0.1%
Study: NCT05601154
Drug: Crest Cavity Protection toothpaste followed by Act Mint Fluoride Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will brush their teeth with Crest Cavity Protection toothpaste (1,100 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of Act Mint Fluoride Rinse (226 ppm) for 1 minute
Study: NCT06678191
Drug: BDP/FF/G (Beclomethasone diprprionate, formoterol fumarate, glycopyrronium bromide) 172/5/9 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: In accordance with the requirements of non-interventional studies, the assignment of patients to Trimbow 172/5/9 μg pMDI therapy should be made independently of the study, and patients should only be considered for inclusion in the study after a prior therapeutic decision has been made by a pulmonologist.
Study: NCT05148702
Drug: Antibiotic - standard duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician decided antibiotic and duration of treatment
Study: NCT05473234
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Children enrolled in the trial and randomized to receive azithromycin will receive a single dose of azithromycin at 20 mg/kg up to the maximum adult dose of 1g. Oral azithromycin will be administered at the time of enrollment. Enrolled children will also receive RUTF.
Study: NCT06504446
Drug: NOC-110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation powder
Study: NCT04639310
Drug: XEN496
Approvals — FDA: no, EMA: no, PMDA: no
Description: XEN496 sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child TID.
Study: NCT04639310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child TID.
Study: NCT05527834
Drug: VNRX-7145
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT04485039
Drug: calcium acetate oral tablet
Normalized name: calcium acetate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: phosphate binder
Study: NCT04918186
Drug: BA3021
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT05786443
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin-matching placebo dosed once-daily over 12 weeks. Administered as oral tablet.
Study: NCT06779968
Drug: Intravenous patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: For intravenous patient-controlled analgesia (PCA), fentanyl was administered at a dose of 2 mcg/kg, diluted in 100 mL of normal saline. The basal infusion rate was set at 2 mL/hr, with a PCA dose of 2 mL and a lockout interval of 15 minutes.
Study: NCT06232759
Drug: Transarterial chemoembolization combined with Tyrosine Kinase Inhibitors and Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with unresectable hepatocellular carcinoma were received transarterial chemoembolization combined with Tyrosine Kinase Inhibitors and Tislelizumab
Study: NCT06780267
Drug: HRS-2129 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-2129 placebo
Study: NCT05425446
Drug: DONQ52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) injection
Study: NCT05425446
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) injection
Study: NCT05478486
Drug: MSP008-22
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is single group assignment interventional model in this clinical trial, consisting of 5 cohorts of 3 patients in each, to be enrolled such that there exists an overall gender balance for the entire trial and to also ensure including minimum five (5) patients of TNBC and minimum five (5) male patients.~The trial will be initiated with dosing of a cohort of 03 patient with the Safe starting dose for MSP008-22. Dosing of the patients for the next higher dose cohort will initiate only after: (i) All 03 patients have been recruited in the lower dose Cohort and if a repeat Cohort at this dose level is recommended, another 03 patients have been recruited at same dose level (ii) all dosed patients have completed the allocated study cohort duration, (iii) safety and pharmacokinetic results have been reviewed by the Independent Dose Escalation Committee (DEC) and approved for dose escalation to next cohort.
Study: NCT05794139
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT06149676
Drug: Saccharomyces Boulardii 250 MG [Florastor]
Normalized name: Saccharomyces boulardii 250 MG [Florastor]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will get the probiotic to be taken daily. If UTI occurs with a sensitive pathogen, we will treat with ciprofloxacin
Study: NCT05010772
Drug: Decitabine and Cedazuridine
Normalized name: cedazuridine / decitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06780670
Drug: Investigators choice of SoC
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control treatment in Phase III is investigator's choice of SoC
Study: NCT06780670
Drug: AAA817
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational treatment is AAA817
Study: NCT06780670
Drug: AAA817
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational treatment is the Dose B of AAA817